Screener
Danaher DHR Biotechnology — Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Danaher in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Danaher’s 10-Q, filed July 21, 2026.
- Filed
- Jul 20, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000313616-26-000161
| For the Three-Month Period Ended June 26, 2026: | Biotechnology / For the Three-Month Period Ended June 26, 2026: | Life Sciences | Diagnostics | Total |
|---|---|---|---|---|
| Western Europe | 689 | 421 | 430 | 1,540 |
| Other developed markets(b) | 74 | 126 | 93 | 293 |
| High-growth markets(c) | 574 | 573 | 811 | 1,958 |
| Total | $1,920 | $1,879 | $2,466 | $6,265 |
| Revenue type: | ||||
| Recurring | $1,722 | $1,268 | $2,210 | $5,200 |
| Nonrecurring | 198 | 611 | 256 | 1,065 |
| Total | $1,920 | $1,879 | $2,466 | $6,265 |
Item 1. Financial Statements
FAQ
- What is Danaher's biotechnology — sales?
- Danaher (DHR) reported biotechnology — sales of $1.92B in Q2 2026.
- How has Danaher's biotechnology — sales changed year-over-year?
- Danaher's biotechnology — sales increased by 3.8% year-over-year, from $1.85B to $1.92B.
- What is the long-term trend for Danaher's biotechnology — sales?
- Over 4 years (2021 to 2025), Danaher's biotechnology — sales has grown at a -4.0% compound annual growth rate (CAGR), from $8.57B to $7.29B.
- What does biotechnology — sales mean?
- Represents the total revenue generated from the sale of products and services within the biotechnology business segment. This metric reflects the market demand for the segment's scientific instruments and consumables. It serves as a primary indicator of the segment's top-line growth and market penetration.
Ask your AI about Danaher's biotechnology — sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude